DK3630112T3 - Kombination af regorafenib og nivolumab til behandling af cancer - Google Patents

Kombination af regorafenib og nivolumab til behandling af cancer Download PDF

Info

Publication number
DK3630112T3
DK3630112T3 DK18725258.0T DK18725258T DK3630112T3 DK 3630112 T3 DK3630112 T3 DK 3630112T3 DK 18725258 T DK18725258 T DK 18725258T DK 3630112 T3 DK3630112 T3 DK 3630112T3
Authority
DK
Denmark
Prior art keywords
regorafenib
nivolumab
cancer
treatment
combination
Prior art date
Application number
DK18725258.0T
Other languages
Danish (da)
English (en)
Inventor
Dieter Zopf
Sabine Hoff
Lars Röse
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK3630112T3 publication Critical patent/DK3630112T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DK18725258.0T 2017-06-02 2018-05-25 Kombination af regorafenib og nivolumab til behandling af cancer DK3630112T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
DK3630112T3 true DK3630112T3 (da) 2024-04-22

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18725258.0T DK3630112T3 (da) 2017-06-02 2018-05-25 Kombination af regorafenib og nivolumab til behandling af cancer

Country Status (22)

Country Link
US (4) US11951166B2 (https=)
EP (2) EP4342542A3 (https=)
JP (3) JP7303122B2 (https=)
KR (2) KR102843438B1 (https=)
CN (3) CN117582495A (https=)
AU (2) AU2018276273B2 (https=)
BR (1) BR112019025478A8 (https=)
CA (2) CA3244313A1 (https=)
DK (1) DK3630112T3 (https=)
ES (1) ES2978337T3 (https=)
FI (1) FI3630112T3 (https=)
HR (1) HRP20240551T1 (https=)
HU (1) HUE066487T2 (https=)
IL (2) IL317015A (https=)
LT (1) LT3630112T (https=)
MX (1) MX2023001721A (https=)
PE (2) PE20200859A1 (https=)
PL (1) PL3630112T3 (https=)
PT (1) PT3630112T (https=)
RS (1) RS65488B9 (https=)
SI (1) SI3630112T1 (https=)
WO (1) WO2018219807A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3244313A1 (en) * 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
TW202539722A (zh) * 2023-12-01 2025-10-16 耶魯大學 治療癌症的組合物和方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1948144A2 (en) 2005-11-10 2008-07-30 Bayer HealthCare AG Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) * 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
EP2900269B1 (en) * 2012-09-25 2018-08-01 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
WO2015125652A1 (ja) 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
EP3563870A1 (en) 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
KR20230030022A (ko) 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
WO2017210119A1 (en) 2016-06-03 2017-12-07 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
CA3244313A1 (en) * 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CR20190550A (es) * 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Also Published As

Publication number Publication date
CN110662540A (zh) 2020-01-07
IL270948B1 (en) 2025-03-01
KR102843438B1 (ko) 2025-08-06
SI3630112T1 (sl) 2024-06-28
US11517622B2 (en) 2022-12-06
RU2019143599A3 (https=) 2021-09-10
ES2978337T3 (es) 2024-09-10
BR112019025478A2 (pt) 2020-06-23
RU2019143599A (ru) 2021-07-09
PL3630112T3 (pl) 2024-07-01
EP3630112B1 (en) 2024-01-31
KR102673422B1 (ko) 2024-06-07
LT3630112T (lt) 2024-05-10
EP3630112B9 (en) 2024-06-26
US20220133888A1 (en) 2022-05-05
WO2018219807A1 (en) 2018-12-06
JP2024096905A (ja) 2024-07-17
CN117582495A (zh) 2024-02-23
JP7303122B2 (ja) 2023-07-04
PT3630112T (pt) 2024-04-23
HUE066487T2 (hu) 2024-08-28
JP7806119B2 (ja) 2026-01-26
HRP20240551T1 (hr) 2024-07-05
CA3244313A1 (en) 2025-06-13
EP3630112A1 (en) 2020-04-08
CN110662540B (zh) 2024-01-26
US20200155674A1 (en) 2020-05-21
AU2018276273A1 (en) 2019-12-12
US20200179354A1 (en) 2020-06-11
IL270948B2 (en) 2025-07-01
EP4342542A2 (en) 2024-03-27
US11951166B2 (en) 2024-04-09
PE20242220A1 (es) 2024-11-19
MX2023001721A (es) 2023-02-22
CA3065125A1 (en) 2018-12-06
PE20200859A1 (es) 2020-08-25
AU2023282197A1 (en) 2024-01-04
JP2022169780A (ja) 2022-11-09
BR112019025478A8 (pt) 2022-12-06
CN117899212A (zh) 2024-04-19
IL317015A (en) 2025-01-01
RS65488B1 (sr) 2024-05-31
US20200188372A1 (en) 2020-06-18
KR20240091188A (ko) 2024-06-21
FI3630112T3 (fi) 2024-05-02
AU2023282197B2 (en) 2025-06-26
RS65488B9 (sr) 2024-09-30
AU2018276273B2 (en) 2023-12-21
IL270948A (en) 2020-01-30
JP2020521786A (ja) 2020-07-27
JP7475402B2 (ja) 2024-04-26
KR20200011971A (ko) 2020-02-04
CA3065125C (en) 2025-06-10
EP4342542A3 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
IL269150A (en) Compositions and methods for treating cancer
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
IL268814A (en) Compositions and methods for treatment of cancer
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3380495T3 (da) Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
IL269157A (en) Compositions and methods for treating cancer
DK3773738T3 (da) Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3493812T3 (da) Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3576740T3 (da) Cancerbehandling
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3691649T3 (da) Sammensætninger og fremgangsmåder til sårbehandling
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne